Report #2900724

Received Jun 19, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: Jun 6, 2026
Onset: Jun 7, 2026
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	—	—

Symptoms (3)

AstheniaDiarrhoeaVomiting

Symptom narrative

Weakness; Severe vomiting; Diarrhea; This non-serious case was reported by a consumer and described the occurrence of weakness in a 66-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included irritable bowel syndrome and gastroesophageal reflux disease. Concomitant products included famotidine (Pepcid). On 06-JUN-2026, the patient received Shingrix. On 07-JUN-2026, 1 days after receiving Shingrix, the patient experienced weakness (Verbatim: Weakness), vomiting (Verbatim: Severe vomiting) and diarrhea (Verbatim: Diarrhea). On 09-JUN-2026, the outcome of the weakness, vomiting and diarrhea were resolved. It was unknown if the reporter considered the weakness, vomiting and diarrhea to be related to Shingrix. Additional Information: GSK Receipt Date: 16-JUN-2026 The batch number was not provided, and we are unable to contact the reporter.

Current illness

Gastroesophageal reflux disease; Irritable bowel syndrome

Other medications

Pepcid